Nuvation Bio CSO receives 748,130 stock options

Hattersley Gary reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Hattersley Gary reported acquisition or exercise transactions in this Form 4 filing.

Nuvation Bio Inc. reported that its Chief Scientific Officer, Gary Hattersley, received a grant of stock options covering 748,130 shares of common stock. The options were awarded at a grant price of $0.00 per option, reflecting a non-cash compensation award rather than an open-market purchase.

According to the vesting terms, 25% of the option grant will vest on the one-year anniversary of 2/27/2026, with the remaining portion vesting in equal monthly installments over the following 36 months, subject to his continuous service on each vesting date.

Insider Trade Summary

Grant/Award: 748,130 shares

Grant/Award 1 txn

Insider Hattersley Gary

Role CHIEF SCIENTIFIC OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	748,130	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 748,130 contracts (Direct)

Footnotes (1)

1. F1. Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NUVB report for Gary Hattersley?

Nuvation Bio reported that Chief Scientific Officer Gary Hattersley received a grant of stock options for 748,130 shares. This is an equity compensation award, recorded at a grant price of $0.00 per option, rather than a market purchase of existing shares.

How many NUVB stock options were granted to the Chief Scientific Officer?

Gary Hattersley was granted stock options covering 748,130 shares of Nuvation Bio common stock. This grant represents a single derivative transaction reported on the Form 4, increasing his directly held derivative position to a total of 748,130 options after the transaction.

What is the vesting schedule for Gary Hattersley’s NUVB option grant?

The option vests as to 25% of the shares on the one-year anniversary of 2/27/2026. The remaining shares then vest in equal monthly installments over the following 36 months, provided he remains in continuous service on each vesting date.

Did Gary Hattersley buy or sell Nuvation Bio shares in this Form 4?

The Form 4 shows an acquisition of derivative securities through an option grant, not a buy or sell of existing shares. The transaction is coded as an award (code A), reflecting a grant of 748,130 stock options as compensation.

Is the NUVB option grant to Gary Hattersley a direct or indirect holding?

The reported stock option grant is classified as a direct holding by Gary Hattersley. The ownership code is “D” for direct, and no footnotes indicate that the options are held through another entity such as a trust, partnership, or family vehicle.

What does transaction code “A” mean in the NUVB Form 4 filing?

Transaction code “A” on this Form 4 indicates a grant, award, or other acquisition of securities. In this case, it reflects a compensation award of 748,130 stock options, consistent with the description of a stock option (right to buy) derivative security.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 07:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hattersley Gary

(Last) (First) (Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.91	02/27/2026		A		748,130		(1)	02/26/2036	Class A Common Stock	748,130	$0	748,130	D

Explanation of Responses:

1. Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

	/s/ Stephen Dang, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.